[DEBUG-WINDOW 처리영역 보기]
BRIC을 시작페이지로 회원가입    로그인
BRIC농수식품
   
통합검색
배너1 배너2 배너3 스폰서배너광고 안내
오늘의 BRIC정보
모바일 BRIC RSS
트위터 페이스북
검색 뉴스레터 안내
좋은 연구문화 만들기
Bio일정
Bio일정
 
Bio일정 프리미엄(유료) 등록이란?
2018 IUBMB SEOUL Plenary Lecture VOD
실험
실험
바이오 형광사진
실험의 달인들
Bio마켓
Bio마켓
BioJob
BioJob
Biojob 프리미엄(유료) 등록이란?
커뮤니티
커뮤니티
대통령과 과학기술자
전체메뉴
대메뉴안내: 농수식품
농림성과 수산성과 식품성과 인터뷰
사진없음
최재일 (J Choi) 저자 이메일 보기
계명대학교 의과대학
조회 455  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Role of the histone deacetylase inhibitor valproic acid in high-fat diet-induced hypertension via inhibition of HDAC1/angiotensin II axis

J Choi1, S Park1, T K Kwon2, S-I Sohn3, K M Park4 and J I Kim1,*

1
Department of molecular Medicine and Medical Research Center, Keimyung University School of Medicine, Daegu, Republic of Korea
2Department of Immunology and Medical Research Center, Keimyung University School of Medicine, Daegu, Republic of Korea
3Department of Neurology and Medical Research Center, Keimyung University School of Medicine, Daegu, Republic of Korea
4Department of Anatomy and BK21 plus, Kyungpook National University School of Medicine, Daegu, Republic of Korea

*Correspondence: Professor JI Kim, Department of Molecular Medicine and Medical Research Center, Keimyung University School of Medicine, 1095 Dalgubeol-Daero, Dalseo-Gu, Daegu 42601, Republic of Korea.

Abstract
BACKGROUND: Obesity is known as an epidemic worldwide because of consumption of westernized high-fat diets and one of the major risk factors of hypertension. Histone deacetylases (HDACs) control gene expression by regulating histone/non-histone protein deacetylation. HDAC inhibitors exert anti-cancer and anti-inflammatory effects and play a protective role in cardiovascular diseases. In the present study, we tested the effect of an FDA-approved pan-HDAC inhibitor valproic acid (VPA) on high-fat diet (HFD)-induced hypertension in mice. Further, we examined the mechanism of VPA-induced prevention of hypertension.

METHODS: Nine-week-old male C57BL/6 mice were fed either a normal diet (ND) or HFD. When the HFD group reached a pre-hypertensive phase (130-140 mm Hg systolic blood pressure), VPA was administered for 6 days (300mg·kg-1·day-1). Body weights and blood pressure (BP), expression of renin-angiotensin system (RAS) components and HDAC1 were determined. The direct role of HDAC1 in the expression of RAS components was investigated using gene silencing.

RESULTS: HFD accelerated the increase in body weight from 22.4±1.3 to 31.9±3.0 compared to in the ND group from 22.7±0.9 to 26.0±1.7 (P=0.0134 ND vs HFD), systolic BP from 118.5±5.7 to 145.0±3.0 (P<0.001), and diastolic BP from 91.0±13.6 to 121.0±5.0 (P=0.006); BP was not altered in the ND group. HFD increased RAS components and HDAC1 in the kidneys as well as leptin in the plasma. VPA administration prevented the progression of hypertension and inhibited the increase in expression of HDAC1 and RAS components. VPA did not affect plasma leptin level. Knockdown of HDAC1 in MDCK cells decreased the expression of angiotensinogen and type1 angiotensin II receptor.

CONCLUSIONS: VPA prevented HFD-induced hypertension by downregulating angiotensin II and its receptor via inhibition of HDAC1, offering a novel therapeutic option for HFD-induced hypertension.

논문정보
- 형식: Research article
- 게재일: 2017년 07월 (BRIC 등록일 2017-08-03)
- 연구진: 국내연구진 태극기
  댓글 0
등록
 
목록
(주)신코
외부관련링크
Google scholar (by J Choi)
Pubmed (by J Choi)
프리미엄 Bio일정 Bio일정 프리미엄 안내
강북삼성병원 개원 50주년 기념 국제심포지엄
강북삼성병원 개원 50주년 기념 국제심포지엄
사전접수: ~2018.07.18
날짜: 2018.07.20
장소: 중앙일보빌딩 호암아트홀 (서울시 중구 서소문로 100)
의료기기 임상시험의 이해 과정
의료기기 임상시험의 이해 과정
날짜: 2018.06.27~29
장소: 경기도 성남시 분당구 판교역로 182 한국반도체산업협회 건물 9층
임상시험 관리 과정
임상시험 관리 과정
날짜: 2018.06.20~22
장소: 경기도 성남시 분당구 대왕판교로 700 코리아바이오파크 B동 지하1층 세미나실
[The 12th Catholic International Stem Cell Symposium] 제12차 가톨릭국제줄기세포심포지엄
[The 12th Catholic International Stem Cell Symposium] 제12차 가톨릭국제줄기세포심포지엄
초록접수: ~2018.06.10
사전접수: ~2018.06.24
날짜: 2018.06.29
장소: 가톨릭대학교 성의교정 마리아홀(서울 반포)
이전페이지로 돌아가기 맨위로 가기
 

BRIC 홈    BRIC 소개    회원    검색    문의/FAQ    광고    후원
Copyright © BRIC. All rights reserved. Contact member@ibric.org

 
에펜도르프코리아